New combo therapy targets hard-to-treat pancreatic cancer liver spread
NCT ID NCT07333287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new first-line treatment for people with pancreatic cancer that has spread to the liver. The treatment combines chemotherapy delivered directly to the liver with two immunotherapy drugs. The goal is to see if this approach can slow or stop cancer growth. The study plans to enroll 38 adults who have not had prior treatment for their advanced cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY-NAIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.